Cellular Renaissance: Manufacturing Market Poised to Reach US$ 15,634.67 Million Valuation by 2033

The global Cell Therapy Manufacturing Market is expected to be worth US$ 4,134.48 million in 2023 and to grow at a 14.2% CAGR from 2023 to 2033. By the end of 2033, the market is expected to be worth US$ 15,634.67 million. Autologous cell therapy manufacturing is the global market leader, accounting for approximately 56.0% of the market in 2021.

Market revenue through Cell Therapy Manufacturing is expected to be the highest revenue-generating segment, accounting for an expected CAGR of 31.8% from 2023 to 2033. The augmenting frequency of cancer and other target diseases, combined with increasing research and development spending in pharmaceutical companies, are driving market expansion.

Immunotherapy, gene transfer, and oncolytic virotherapy are three separate gene therapy treatments that are excessively utilized to treat cancer. As the number of instances increases, so will the reliance on gene therapy, thus driving the market growth. In addition to that, it has been estimated that more than 50 million people will be diagnosed with cancer within the next five years.

Take the first step towards enhanced performance and unmatched efficiency today! Request Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16515

Report Highlights:

Breast cancer has significantly suppressed lung cancer, by being one of the most commonly diagnosed cancers worldwide. For the first time, owing to its high incidence in low- and middle-income nations. Because cancer is one of the most complex diseases, cell and gene therapy is one of the fields with a significant opportunity for cancer treatment.

Aging populations and socioeconomic risk factors are two of the most common causes of cancer cases worldwide. Breast cancer is also one of every four cancers diagnosed in women worldwide, according to the same source.

GLOBOCAN 2020 has been revised by the International Agency for Research on Cancer (IARC), which reveals that the worldwide cancer burden has increased to 19.3 million cases and 10 million cancer deaths in 2020.

Recent Developments:

There are approximately 1,200 cell and gene therapies in clinical trials worldwide. In the USA alone, there are around 700 investigational cell and gene therapies in clinical trials.

Various manufacturing facilities are unable to keep up with global requirements. Hundreds of more facilities are expected to be required to manufacture the therapies currently in clinical development. Viral capacity is one of the areas that has to be accelerated.

A significant portion of the viral vectors is built with adherent manufacturing, which is expensive to run. A vial of 20 million cells is likely to cost anywhere between US$ 20,000 and US$ 30,000 to generate. The cost of producing gene therapy can range from US$ 500,000 to US$ 1 million, excluding research and development, clinical trial costs, and the costs of establishing the commercial infrastructure required to offer access to patients.

Curious? We’ve Got Answers! Unleash Your Questions and Uncover the Knowledge You Seek – Ask Us Anything Today:
https://www.futuremarketinsights.com/ask-question/rep-gb-16515

Competitive Landscape:

The surging interest of key public and private investors in the development of advanced therapies is expected to boost market revenue during the forecast period. In addition, key firms are enhancing their market presence through strategic activities such as mergers and acquisitions, licensing, and partnerships.

Key Companies Profiled:

• Thermo Fisher Scientific
• Merck KGaA
• Lonza
• Catalent Inc.
• Takara Bio Inc.
• F. Hoffmann-La Roche Ltd
• Wuxi Advanced Therapies
• Samsung Biologics
• Boehringer Ingelheim
• Novartis AG
• Hitachi Chemical Co., Ltd.
• Cellular Therapeutics
• Miltenyi Biotec
• Bluebird Bio Inc.

More Insights into this Market:

The North American region is anticipated to dominate the global cell and gene therapy manufacturing market over the forecast period. The U.S.A. accounted for a massive proportion of the market revenues in 2022. The key driving factors for the market expansion in the country are the large number of active clinical trials, as well as the growing engagement of firms in gene and cell therapy research and development. With more than 400 businesses actively engaged in the development of cell and gene therapy products for various diseases, North America was ranked top for having the most gene therapy clinical trials.

The United Kingdom market is expected to showcase a positive growth outlook over the evaluation period. The European region is expected to reach a valuation of US$ 6.5 Billion by 2033. Growing with a CAGR of 23.9% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of US$ 5.7 Billion.

In countries like Japan, the global market is expected to propel at a CAGR of 32.5% from 2023 to 2033, surpassing a valuation of US$ 12.6 Billion by 2033. The market in the country is expected to gross an absolute dollar opportunity of US$ 11.9 Billion during the forecast period.

Insights Designed for You: Customize Your Exclusive Report Today :
https://www.futuremarketinsights.com/customization-available/rep-gb-16515

Market Segmentation Covered:

By Therapy Type:

• Cell Therapy Manufacturing
  • Stem Cell Therapy
  • Non-Stem Cell Therapy
• Gene Therapy Manufacturing

By Scale:

• Pre-commercial/ R&D Manufacturing
• Commercial Scale Manufacturing

By Mode:

• Contract Manufacturing
• In-house Manufacturing

By Workflow:

• Cell Processing
• Cell Banking
• Process Development
• Fill & Finish Operations
• Analytical And Quality Testing
• Raw Material Testing
• Vector Production
• Other Workflows

By Region:

• North America
  • USA
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of the Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:          

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube